Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020
The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 provides comprehensive understanding and unprecedented access to clinical stage partnering agreements entered into by the worlds leading biopharma companies
The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014 - 2020 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 2,300 clinical stage partnering deals announced since 2014 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of clinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner clinical stage compounds/products.
Chapter 3 provides an overview of clinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in clinical stage deals.
Chapter 5 provides a review of clinical stage deal making since 2014. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.
Chapter 6 provides a detailed analysis of clinical stage payment terms including headline, upfront, milestone and royalty rates for phase I, phase II and phase III deals.
Chapter 7 provides a review of the leading clinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 8 provides a comprehensive listing of the top 25 most active clinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 9 provides a comprehensive and detailed review of clinical stage partnering deals signed and announced since 2014, where a contract document is available in the public domain.
Chapter 10 provides a comprehensive directory of clinical stage partnering deals since 2014 organized by stage of development – phase I, phase II and phase III.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous tables and figures that illustrate the trends and activities in clinical stage partnering and deal making since 2014.
In addition, a comprehensive appendix of all clinical stage deals since 2014 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of clinical stage products and compounds.
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014 - 2020 provides the reader with the following key benefits:
- In-depth understanding of clinical stage deal trends since 2014
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of clinical stage agreements with numerous real life case studies
- Insight into the terms included in a clinical stage agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2020 is intended to provide the reader with an in-depth understanding and access to clinical stage deal trends and structure of deals entered into by leading companies worldwide.
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2020 includes:
- Trends in clinical stage dealmaking in the biopharma industry since 2014
- Analysis of clinical stage deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life clinical stage deals
- Access to over 2,300 clinical stage deals
- The leading clinical stage deals by value since 2014
- Most active clinical stage dealmakers since 2014
- The leading clinical stage partnering resources
In Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2020, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal type
- Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014 - 2020 report provides comprehensive access to available deals and contract documents for over 2,300 clinical stage deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 provides the reader with the following key benefits:
- In-depth understanding of clinical stage deal trends since 2014
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 2,300 clinical stage deals together with contract documents if available
- Detailed access to actual clinical stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
- Analysis of the structure of clinical stage agreements with numerous real life case studies
- Identify leading clinical stage deals by value since 2014
- Identify the most active clinical stage dealmakers since 2014
- Full listing of clinical stage deals by company A-Z, phase of development, deal type, therapy and technology focus
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Chapter 1 – Introduction
Chapter 2 – Why do companies partner clinical stage compounds?
2.2. The role of clinical stage partnering
2.2.1. In-licensing at clinical stage
2.2.2. Out-licensing at clinical stage
2.3. Difference between phase I, II and III stage deals
2.4. Reasons for entering into clinical stage partnering deals
2.4.1. Licensors reasons for entering clinical stage deals
2.4.2. Licensees reasons for entering clinical stage deals
2.5. The future of clinical stage partnering deals
Chapter 3 – Clinical stage deal strategies and structure
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech
126.96.36.199. Discovery and preclinical stage partnering case studies
188.8.131.52.a. Case study: LEO Pharma - 4SC
184.108.40.206.b. Case study: Heptares Therapeutics - Cubist
220.127.116.11.c. Case study: Incyte – Agenus Bio
18.104.22.168.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
22.214.171.124. Clinical stage partnering case studies
126.96.36.199.a. Case study: Servier – GeNeuro
188.8.131.52.b. Case study: Teva – Xenon Pharmaceuticals
184.108.40.206.c. Case study: AstraZeneca - Ardelyx
220.127.116.11.d. Case study: Baxter – Onconova Therapeutics
3.3. Early and later stage partnering – a risk/cost comparison
3.4. What do companies spend on clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.6.1.a. Case study : Argos Therapeutics – Medinet
3.6.1.b. Case study : Pfizer - GlycoMimetics
3.7. Multicomponent clinical stage partnering agreements
3.7.1. Example multicomponent clinical stage clauses
3.7.1.a. Case study: Gilead Sciences – GlobeImmune
Chapter 4 – Clinical stage partnering payment strategies
4.2. Clinical stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
18.104.22.168. Conditionality of upfront payments
4.3.4. Convertible loans
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
22.214.171.124. Issues affecting royalty rates
126.96.36.199. Royalties on combination products
188.8.131.52.a. Case study: Scripps Research Institute-Cyanotech
184.108.40.206. Guaranteed minimum/maximum annual payments
220.127.116.11. Royalty stacking
18.104.22.168. Royalties and supply/purchase contracts
4.3.11. Option payments
Chapter 5 – Trends in clinical stage deal making
5.2. Clinical stage partnering over the years
5.2.1. Trends in phase I deals since 2014
22.214.171.124. Attributes of phase I deals
5.2.2. Trends in phase II deals since 2014
126.96.36.199. Attributes of phase II deals
5.2.3. Trends in phase III deals since 2014
188.8.131.52. Attributes of phase III deals
5.3. Clinical stage partnering by deal type
5.4. Clinical stage partnering by disease type
5.5. Partnering by clinical stage technology type
5.6. Clinical stage partnering by most active company since 2014
Chapter 6 – Payment terms for clinical stage partnering
6.2. Guidelines for clinical stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Clinical stage payment terms – deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Clinical stage partnering headline values
6.4.2. Clinical stage deal upfront payments
6.4.3. Clinical stage deal milestone payments
6.4.4. Clinical stage royalty rates
6.5 Clinical stage median financials
6.5.1. Clinical stage headline value
6.5.2. Clinical stage upfront value
6.5.3. Clinical stage milestone value
6.5.4. Clinical stage royalty value
Chapter 7 – Leading clinical stage deals
7.2. Top clinical stage deals by value
Chapter 8 – Top 25 most active clinical stage dealmakers
8.2. Top 25 most active clinical stage dealmakers
Chapter 9 – Clinical stage partnering contracts directory
9.2. Clinical stage deals with contracts since 2014
Chapter 10 – Clinical stage deal making by development stage
10.2. Deals by clinical stage
Appendix 1 – Clinical stage dealmaking by companies A-Z
Appendix 2 – Clinical stage dealmaking by industry sector
Appendix 3 – Clinical stage dealmaking by stage of development
Appendix 4 – Clinical stage dealmaking by therapy area
Appendix 5 – Clinical stage dealmaking by technology type
About Wildwood Ventures
Recent report titles from Current Partnering
Table of figures
Figure 1: Definition of clinical phases in dealmaking
Figure 2: Components of the pure licensing deal structure
Figure 3: Payment options for clinical stage partnering deals
Figure 4: Issues affecting royalty rates
Figure 5: Phase I clinical stage partnering since 2014
Figure 6: Phase II clinical stage partnering since 2014
Figure 7: Phase III clinical stage partnering since 2014
Figure 8: Clinical stage partnering by deal type since 2014
Figure 9: Clinical stage partnering by disease type since 2014
Figure 10: Clinical stage partnering by technology type since 2014
Figure 11: Top 25 most active clinical stage dealmakers, 2014 to 2020
Figure 12: Review of upfront payments for clinical stage deals
Figure 13: Review of milestone payments for clinical stage deals
Figure 14: Review of royalty payments for clinical stage deals
Figure 15: Clinical stage deals with a headline value
Figure 16: Clinical stage deals with an upfront value
Figure 17: Clinical stage deals with a milestone value
Figure 18: Clinical stage deals with a royalty rate value
Figure 19: Summary median headline value by clinical stage of development, 2014-2020
Figure 20: Summary median upfront payments by clinical stage of development, 2014-2020
Figure 21: Summary median milestone payments by stage of development, 2014-2020
Figure 22: Summary median royalty rate by stage of development, 2014-2020
Figure 23: Top clinical stage deals by value since 2014
Figure 24: Most active clinical stage dealmakers 2014 to 2020
- $3,495: single-user
- $5,245: multi-user
- $10,495: single site license
- $17,495: global site license
A full explanation of license type definitions can be found here.
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
All card payments are processed by SagePay.
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
2X Oncology, 3D Medicines, 3M Drug Delivery Systems, 3SBio, 4D Pharma, 4SC, AADi, Abbisko Therapeutics, Abbott Laboratories, Abbott Vascular Devices, Abbvie, Abide Therapeutics, Abiogen Pharma, ABIVAX, ABL Bio, Ablynx, ABX, Acacia Pharma, ACADIA Pharmaceuticals, Acasti Pharma, Acceliant, Accenture, Accord Healthcare, Accurexa, Acell, Acerta Pharma, Acer Therapeutics, Acerus, Aceto Corporation, Acetylon Pharmaceuticals, Achieve Life Science, Achillion Pharmaceuticals, AC Immune, Aclaris Therapeutics, Acrotech Biopharma, ACT Biotech, Actelion, Actigraph, Actinium Pharmaceuticals, ACT Onocology, Acturum Life, Acuity Pharmaceuticals, Acura Pharmaceuticals, Adamas Pharmaceuticals, Adaptimmune, Adaptive Biotechnologies, ADC Therapeutics, Addex Therapeutics, Adlai Nortye, Adocia, Adult Brain Tumor Consortium, Aduro BioTech, Advanced Accelerator Applications, Advanced Biological Laboratories, Advanced BioScience Laboratories, Advaxis, Aeglea BioTherapeutics, Aelix Therapeutics, Aerial BioPharma, Aeromics, Aerpio Therapeutics, AEterna Zentaris, Aethlon Medical, Aevi Genomic Medicine, Affibody, Affimed Therapeutics, Affinium Pharmaceuticals, Agalimmune, AGC Asahi Glass, Agendia, AgeneBio, Agenus Bio, Agilent Technologies, Agios Pharmaceuticals, Agricultural Materials Company, AIDS Clinical Trials Group, Aimmune Therapeutics, AirWare Labs, AiVita Biomedical, AkaRx, Akashi Therapeutics, Akcea Therapeutics, Akebia Therapeutics, Akero Therapeutics, Akili Interactive Labs, AKL Research and Development, Akorn, Alat Medika Indonesia, Albany Molecular Research, Albireo, Alcami, Alder Biopharmaceuticals, Alexion Pharmaceuticals, Alfasigma, AliveGen, ALK-Abello, Alkahest, Alkermes, Allegro Ophthalmics, Allergan, Alliance For Clinical Trials In Oncology, Alliance for Lupus Research, Alligator Bioscience, Allogene Therapeutics, Alloksys Life Sciences, Almirall, Alnylam Pharmaceuticals, Alphamab, Alpine Immune Sciences, ALS Association, Alseres Pharmaceuticals, ALS Finding a Cure Foundation, Altair, Alteogen, Alternavida, Altor BioScience, Altos Group, Alvogen, Alvotech, AlzeCure Pharma, Alzheimer's Drug Discovery Foundation, AlzProtect, AM-Pharma, Amag Pharmaceuticals, Amal Therapeutics, Amarantus BioSciences, Amarex Clinical Research, Amarin, Ambrx, Ambu, Amend Surgical, American Gene Technologies, American National Multiple Sclerosis Society, American Red Cross, American Sexual Health Association, Amerigen Pharmaceuticals, Amgen, Amicus Therapeutics, Amneal Pharmaceuticals, AMO Pharma, Amoy Diagnostics, AMPEL BioSolutions, AmpliPhi Biosciences, Amplyx Pharmaceuticals, AMR, Amygdala Neurosciences, Anatara Lifesciences, Anavex Life Sciences, Andor Pharmaceuticals, Andromeda Biotech, Anergis, Angelini Pharma, Angiochem, Angion Biomedica, Angionetics, AngioSoma, AnHeart Therapeutics, Animatrix Capital, ANI Pharmaceuticals, Anixa Biosciences, Anji Pharma, AnnaMed, Ansell, Antengene, Anthem, Anthera Pharmaceuticals, Anthony Nolan, Antibe Therapeutics, Antigen Express, Antisense Therapeutics, AOP Orphan Pharmaceuticals, AOTI, Apceth, Apexian Pharmaceuticals, Apexigen, APL, Aplagon, Apogee Biotechnology, Apogenix, ApolloBio, Apollomics, Apollo Sugar, Appili Therapeutics, Aprecia Pharmaceuticals, Apricus Biosciences, Apsen Farmacutica, Aptahem, Aquinox Pharmaceuticals, Araclon Biotech, Aranda Pharma, Aratana Therapeutics, Arcadia Biosciences, Arch Biopartners, Archer Daniels Midland Company, Arcoral Pharma, Arcus Biosciences, Ardelyx, Arena Pharmaceuticals, arGEN-X, argenx, Argos Therapeutics, Ariad Pharmaceuticals, Aridis Pharmaceuticals, Aristea Therapeutics, Armetheon, Arno Therapeutics (inactive since 2017), ArQule, Array Biopharma, Arrevus, Arrien Pharmaceuticals, Arrow Pharmaceuticals, Artes Biotechnology, Aruvant Sciences, Arvelle Therapeutics, Asahi Kasei, Ascentage Pharma, Ascletis, ASKA Pharmaceuticals, AskAt, Asklepion Pharmaceuticals, Asklepios Biopharmaceutical, Aslan Pharma, Aspen Holding, Aspire Health Science, Aspyrian Therapeutics, Assurex Health, Assuta Medical Centers, Astellas Pharma, Asterias Biotherapeutics, Astex Pharmaceuticals, AstraZeneca, Astute Medical, ATAI Life Sciences, Atara Biotherapeutics, ATGen Global, Athenex, Athersys, Atlab Pharma, Atlantic Healthcare, Atnahs Pharma, Atossa Genetics, Atrapos Therapeutics, aTyr Pharma, Aucta Pharmaceuticals, Audentes Therapeutics, Auditus, AUM Biotech, Aurinia Pharmaceuticals, Autifony Therapeutics, Autism Speaks, AutoGenomics, Autolus, Autotelic, Auven Therapeutics, Avacta, Avaria Health & Beauty, AVEO Oncology, Avillion, AV Therapeutics, AXIM Biotechnologies, Axovant Sciences, Axsome Therapeutics, Azitra, Baker Brothers Investments, Baruch S Blumberg Institute, Basilea Pharmaceutica, Battelle, Bausch & Lomb, Bausch Health Companies, Bavarian Nordic, Baxalta, Baxter International, Bayer, Bayer Healthcare, Baylor College, Baylor College of Medicine, Baylor Sammons Cancer Center, BDD Pharma, Beckman Coulter, BeiGene, Beijing Clear Biotech, Beijing Genomics Institute (BGI), Beijing SL Pharma, Beike Biotech, Beleave, Bellicum Pharmaceuticals, Bellus Health, Bendalis, Bened Biomedical, BenevolentAI, Benitec Biopharma, Berg, BerGenBio, Berlin Chemie, Besins Healthcare, Be The Match BioTherapies, Betta Pharmaceuticals, Bhang, BHV Pharmaceuticals, Bial, Bicycle Therapeutics, Bill and Melinda Gates Foundation, Bio-Path, Bio-Thera Solutions, BioAlliance Pharma, BioAxone Therapeutic, BioBlast Pharma, BioCardia, BioCryst Pharmaceuticals, bioCSL, BioDelivery Sciences, Biodesix, Bioeq IP, Bio Farma, Biogen, BioGenetics, Biohaven Pharmaceutical Holding, BioInvent, Biokin Pharmaceutical, BiolineRX, BioMarin Pharmaceutical, Biomedical Advanced Research and Development Authority, Biomedical Catalyst Fund (UK), Biomerica, Bioncotech Therapeutics, BiondVax, Bioniz Therapeutics, Biooutsource, Biophore Pharmaceuticals, Bioprojet, BioSense Global, BioSun Pharmed, Biothera, BioTie Therapies, BioVectra, Bioventus, BioXcel, Biscayne Neurotherapeutics, BL&H, BlackThorn Therapeutics, Blake Insomnia Therapeutics, Blanver, Blaze Bioscience, Blinktbi, Bloom Science, Bluebird Bio, Blue Earth Diagnostics, Bluegrass Vascular Technologies, Blueprint Medicines, Boehringer Ingelheim, Bone Therapeutics, Bonify, Bonnie J. Addario Lung Cancer Foundation, Boryung Pharmaceutical, Boston Pharmaceuticals, Boston Strategics, Boston Therapeutics, Botanisol, Bpifrance, BrainScope, BrainStorm Cell Therapeutics, Brammer Bio, BravoVax, Breath Therapeutics, Breckenbridge Pharmaceutical, Breckenridge Pharmaceuticals, BriaCell Therapeutics, Brickell Biotech, BridgeBio Pharma, Bridge Biotherapeutics, Brigham and Women's Hospital, Brill Pharma, Bristol-Myers Squibb, Broad Institute, BTG, Burning Rock, Butantan Institute, C3i, Cachet Pharma, Cadila Pharmaceuticals, Caelum Biosciences, Caladrius Biosciences, California Institute for Regenerative Medicine, California Institute of Technology, Calithera Biosciences, Calliditas Therapeutics, Calox de Costa Rica, Camargo Pharmaceutical Services, Camurus, Can-Fite BioPharma, Canadian Brain Tumour Consortium, Canadian Cancer Trials Group, Canagen Pharmaceuticals, Canbex Therapeutics, CANbridge Life Sciences, Cancer Genetics, Cancer Prevention and Research Institute of Texas, Cancer Prevention Pharmaceuticals, Cancer Research Technology, Cancer Research UK, Cancer Science Institute of Singapore, CanCure, Candel Therapeutics, CanniMed Therapeutics, Cantabria Pharma, Cantargia, Cantex Pharmaceuticals, Canymed, Capricor Therapeutics, Cara Therapeutics, CARB-X, Cardiome Pharma, Cardium Therapeutics, CareDx, CareFirst BlueCross BlueShield, Caris Life Sciences, Carmel Pharma, Carmentix, Carrick Therapeutics, Case Western Reserve University, CASI Pharmaceuticals, Catabasis Pharmaceuticals, Catalent, Catalyst Pharmaceutical Partners, Catapult Therapy TCR, CB2 Insights, CB2 Therapeutics, CBT Pharmaceuticals, Cedars-Sinai Medical Center, Celdara Medical, Celgene, Celimmune, CellAct, Celladon, Cellastra, Cell Cure Neurosciences, Celldex Therapeutics, Cellectar Biosciences, Cellect Biotechnology, Cellectis, CellProThera, Cell Therapy Catapult, Celltrion, Cellular Biomedicine, Cellvation, Cel Sci, Celsion, Celtic Biotech, Celtis Pharm, Celyad, Cempra Pharmaceutical, Censa Pharmaceuticals, Center for Cancer Research, Center for Connected Health, Centers for Disease Control and Prevention, Centogene, Centre for Probe Development and Commercialization, Centre International de Developpment Pharmaceutique, Centre Leon Berard, Centrexion, Centurion, Cerecor, Certara, Cerulean Pharma, Cerus, Cevec Pharmaceuticals, Charite-Universitatsmedizin, Charleston Laboratories, Checkmate Pharmaceuticals, Checkpoint Therapeutics, ChemoCentryx, Chi-Med, Chiesi Farmaceutici, Children's Hospital of Philadelphia, Chimerix, China Medical System, China State Institute of Pharmaceutical Industry (CIPI), Chinese University of Hong Kong, Chong Kun Dang, Chongqing Jingdong Pharmaceutical, ChromaDex, Chugai Pharmaceutical, Chugai Pharma Marketing, Ciclofilin Pharmaceuticals, Cidara Therapeutics, Cilag AG, CiMaas, CIMAB SA, Cincinnati Children’s Hospital Medical Center, CinCor Pharma, Cingulate Therapeutics (CTx), Cipher Pharmaceuticals, Cipla, Citron Pharma, City of Hope, City of Hope Comprehensive Cancer Center, Civica Rx, CJ Corp, Clarus Therapeutics, Clearside Biomedical, Clementia Pharmaceuticals, Clene Nanomedicine, Cleveland BioLabs, Cleveland Clinic, Cleveland Diabetes Care, Clinical Genomics, Clinical Network Services, Clinigen, Clinipace Worldwide, Clovis Oncology, CMAB Biopharma, CMC Biologics, CMS Medical, CNS Pharmaceuticals, Coalition for Epidemic Preparedness Innovations, Codexis, Cofactor Genomics, Cognition Therapeutics, Coherus Biosciences, Cold Genesys, Coldstream Laboratories, Collaborative Study Group, Collegium Pharmaceuticals, Color Genomics, Columbia Care, Columbia University, Complement Pharma, Compugen, Conatus Pharmaceuticals, Concert Pharmaceuticals, Confluence Pharmaceuticals, Connecticut Innovations, Constance Therapeutics, Context Therapeutics, ContraVir Pharmaceuticals, ConverGene, Cook Biotech, Cook Medical, Corbus Pharmaceuticals, Corcept Therapeutics, CORD:USE, CoreRx Pharma, Corino Therapeutics, Cornell University, Correvio, Cortendo, Cortex Pharmaceuticals, CorVascular, Corvus Pharmaceuticals, Cosmo Pharmaceuticals, COUR Pharmaceutical, Covance, Crescita Therapeutics, Crestone Pharma, CRISPR Therapeutics, Crohn's and Colitis Foundation of America, CR Pharma, CRT Pioneer Fund, Cryolife, CryoPort, CrystalGenomics, CSL, CSPC Pharmaceutical Group, CStone Pharmaceuticals, CTD Holdings, CTI BioPharma, Cullinan Oncology, Cumberland Pharmaceuticals, Cura Partners, CURE Pharmaceutical, Cures Within Reach, Curetis, Curium, Currax Pharmaceuticals, CURx Pharmaceuticals, Custopharm, Cutaneous Lymphoma Foundation, Cyclacel Pharmaceuticals, Cycle Pharmaceuticals, Cyclopharm, Cyclo Therapeutics, CymaBay Therapeutics, Cynapsus Therapeutics, Cyntec, Cynvenio, Cyon Therapeutics, Cyprium Therapeutics, Cyrenaic Pharmaceuticals, Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, CytImmune Science, Cytodyn, Cytokinetics, Cytori Therapeutics, CytoSen Therapeutics, Cytovance Biologics, Cytovation, Cyxone, Daewoong Pharmaceutical, Daiichi Sankyo, Dainippon Sumitomo Pharma, Dako, DalCor Pharmaceuticals, Dalhousie University, Dalton Pharma Services, Dana-Farber Cancer Institute, Dance Biopharm, DanDrit Biotech, DARA BioSciences, Dare Bioscience, Dassault Systems, DAS Therapeutics, Davospharma, DBV Technologies, DCPrime, Debiopharm, DecImmune Therapeutics, Deciphera Pharmaceuticals, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, Delcath Systems, DelMar Pharmaceuticals, Deltamune, Denali Therapeutics, Denovo Biopharma, Department of Defense, Department of Health and Human Services, Department of Veterans Affairs, Dermavant Sciences, Dermin, Dermira, Destiny Pharma, DeuteRx, Dexcel Pharma, DiaMedica, Dilafor, Dilaforette, Dipexium Pharmaceuticals, Discovery Laboratories, Diurnal, DNAtrix, Domainex, Dong-A Pharmaceutical, Dongbao, Dr. Falk Pharma, Dr. Reddy's Laboratories, Dragonfly Therapeutics, DreaMed Diabetes, Drugs for Neglected Diseases Initiative, DSG, DuChemBio, Duchenne UK, Duchesnay, Duke-NUS Graduate Medical School Singapore, Duke Cancer Institute, Duke University, Durata Therapeutics, Durect, Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON), Dynasil, Dynavax Technologies, Dyne Therapeutics, DynPort Vaccine Company, DySIS Medical, Dystonia Medical Research Foundation, Eagle Pharmaceuticals, Eastar Industries, Eastern Cooperative Oncology Group, EB Pharma, EDAP TMS, Eddingpharm, Edge Medical, Edison Pharmaceuticals, Educational and Scientific, eFFECTOR Therapeutics, EffRx, EGeen, EicOsis, Eiger BioPharmaceuticals, EirGenix, EirGen Pharma, Eisai, Eisai Inc, Elanco, Eleven Biotherapeutics, Elicio Therapeutics, Eli Lilly, Elite Pharmaceuticals, Ellipses Pharma, Emerald Logic, Emerge Health, Emergent BioSolutions, Emmaus Life Sciences, Emmes, Emory University, EMS, Emtora Biosciences, EndoCeutics, Endocyte, Endo International, EndoLogic, Endo Pharmaceuticals, Endospan, Enlivex, Entasis Therapeutics, Enteris Biopharma, Enterome Bioscience, Enterprise Therapeutics, Enumeral Biomedical, Eolas Therapeutics, Epic Pharmaceuticals, Epic Sciences, EpiDestiny, Epirus Biopharmaceuticals, EpiThany, Epizyme, Equinox Science, Erasmus University Medical Center, Ergomed, Erytech, Especificos Stendhal, Esperance Pharmaceuticals, Esperion Therapeutics, Esteve, Eton Pharmaceuticals, Eu Hwa, Eunice Kennedy Shriver Institute of Child Health and Human Development, Eureka Therapeutic, Eurofarma, European Commission, European Organization for Research and Treatment of Cancer, European Union, EUSA Pharma, Eutropics Pharmaceuticals, Everest Medicines, Eversana, Evestra, Evoke Pharma, Evolva, Evolve BioSystems, Evonik Industries, Exalenz Bioscience, ExeGi Pharma, Exelixis, Exicure, EyePoint Pharmaceuticals, Eyevance, F-Star Alpha, F1 Oncology, F2G, Fabre Kramer Pharmaceuticals, Fagron, Fair Access Medicines, Fannin, Faron Pharmaceuticals, Federal Ministry of Education and Research (BMBF), Fedora Pharmaceuticals, Felkasta JSC, Ferrer International, Ferring Pharmaceuticals, FightMND, First Horizon Pharmaceuticals, Five Prime Therapeutics, FKD Therapies, FluGen, FLX Bio, Food and Drug Administration (FDA), Forbius, Forendo Pharma, Foresee Pharmaceuticals, FORMA Therapeutics, Forty Seven, Fosun Pharmaceutical, Foundation Fighting Blindness, Foundation Medicine, Fred Hutchinson Cancer Research Center, Freenome, Frequency Therapeutics, Fresenius Medical Care, Frontida BioPharm, FSD Pharma, Fuhong Hanlin, Fujifilm, Fujifilm Kyowa Kirin Biologics, Fujifilm Pharma, Fuji Pharma, Fulcrum Therapeutics, FusionHealth, G-treeBNT, G1 Therapeutics, GABA Therapeutics, Galapagos, Galderma, Galectin Therapeutics, Galecto Biotech, Galena Biopharma, Galmed Pharmaceuticals, Gamida Cell, GB Sciences, GC Pharma, Gebro Pharma, Gecko Biomedical, Gedeon Richter, GE Healthcare, Gemphire, Genentech, GeneOne Life Science, GenePeeks, Generex Biotechnology, Generon, GenesisCare, GeNeuro, Genexine, Genfit, Genmab, Genocea Biosciences, Genome and Company, Genor Biopharma, Genprex, GenSpera, Genzyme, Geom Therapeutics, Georgetown University, George Washington University, Georgia Regents University in Augusta, GeoVax, Geron, GI Dynamics, Gilead Sciences, GISCAD Foundation, Gland Pharma, Glaukos, GlaxoSmithKline, GL Brands, Glenmark Pharmaceuticals, GliaCure, Glide, Global Antibiotic Research and Development Partnership, Global Blood Therapeutics, Global Drug Development Centre (GDCC) China, Globavir Biosciences, GlycoMimetics, GOG Foundation, Goodwin Biotechnology, Gossamer Bio, Government of Canada, Gradalis, Grifols, Gritstone Oncology, Grow Biotech, Grunenthal, Grupo Ferrer, Grupo Juste, GT Biopharma, Guangzhou Pharmaceutical Group, Guangzhou Xiangxue Pharmaceutical, Guardant Health, Guided Therapeutics, Gurnet Point Capital, GW Pharmaceuticals, GYD, Hadasit Bioholdings, Hadasit Medical Research Services and Development, Hadassah Medical Center, Hainan Sihuan Pharmaceutical, HalioDx, Halozyme Therapeutics, Hamilton Health Sciences, HanAll Pharmaceuticals, Hanmi Pharmaceutical, Hannover Medical School, HanX Biopharmaceuticals, Harbour Biomed, Harmony Biosciences, Harpoon Therapeutics, Harvard Medical School, Harvard University, Harvest One, Healios K.K., Healthcare Royalty Partners, HealthCore, Health Decisions, Health House International, Heat Biologics, HEC Pharm, Hefei Life Science, Heidelberg Pharma, Helius Medical Technologies, Helix BioPharma, Helsinn Healthcare, Helsinn Therapeutics, HemispheRx Biopharma, Hemostemix, Henan Province People's Hospital, Henlius Biotech, Heritage Pharmaceuticals, Hill Dermaceuticals, Histocell, HistoIndex, Hitachi Chemical, HLS Therapeutics, Hoba Therapeutics, Hoffmann La Roche, Honda R&D Americas, Hoosier Cancer Research Network, Horizon 2020, Horizon Pharma plc, Hospira, Houston Pharmaceuticals, HPGC Medical, Huapont Pharma, Humabs BioMed, Humacyte, Human Biosystems, Humanetics, Humanigen, Hummingbird Bioscience, Huons, Hutchison MediPharma, Hy BioPharma, Hyundai Pharmaceutical, I-mab, Icahn School of Medicine at Mount Sinai, iCardiac Technologies, IceCure Medical, Ichnos Sciences, ICM, Icon, Idera Pharmaceuticals, Idorsia, IDT, Ignyta, Ikaria, ILTOO Pharma, Image Analysis, ImageIQ, ImaginAb, Immatics Biotechnologies, Immodulon Therapeutics, Immune Design, Immune Pharmaceuticals, ImmunID Technologies, Immunitor, ImmunoCellular Therapeutics, Immunocore, ImmunoGen, Immunomedics, Immunomic, Immunovaccine, Immunovia, ImmuPharma, Immutep, IMPACT Therapeutics, Impax Laboratories, Imperial College London, Imperial Innovations, Impopharma, Inceptua, INC Research, Incyte, InDex Pharmaceuticals, Indivior, Infectious Disease Research Institute (IDRI), Infinity Pharmaceuticals, Inflection Biosciences, Inform Genomics, Innate Pharma, Innovate Biopharmaceuticals, Innovate UK, Innovation Pharmaceuticals, Innovative Cellular Therapeutics, Innovent Biologics, Innovus Pharmaceuticals, INO Therapeutics, Inovio, Inovio Pharmaceuticals, Inserm, Inserm Transfert, Inspirion Delivery Sciences, Institute of Human Virology, Institut Gustave Roussy, Intarcia Therapeutics, Intec, Integrity Applications, IntelGenx, IntelliCell BioSciences, Intellipharmaceutics, Intensity Therapeutics, InterCure, Interleukin Genetics, International Duchenne Alliance, International Medica Foundation, InteRx Biomedical, iNtRON Biotechnology, Intuitive Surgical, Invectys, Inventia Healthcare, InventisBio, inVentiv Health, INVO Bioscience, InxMed, IO Biotech, Ion Channel Innovations, Ionis Pharmaceuticals, Io Therapeutics, Iovance Biotherapeutics, iPharma, Ippox Foundation, Ipsen, IPS Specials, Iroko Pharmaceuticals, Ironwood Pharmaceuticals, IRX Therapeutics, ISA Pharmaceuticals, Isarna Therapeutics, ISA Scientific, Islet Sciences, Isofol Medical, IsoTherapeutics, Israeli Ministry of Industry and Commerce, Israeli National Authority for Technological Innovation, Israel Investment Center, iTeos Therapeutics, ITM Isotopen Technologien, Iveric Bio, Ivy Brain Tumor Center, IXICO, Izana Bioscience, Jackson Laboratory, Jain Foundation, JAMP Pharma Group, JanOne, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Sciences, Japan Tobacco, Jazz Pharmaceuticals, JDP Therapeutics, Jeffrey Modell Foundation, Jerome Stevens Pharmaceuticals, Jiangsu Alphamab, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu NHWA Pharmaceutical, Jinzhou Ahon Pharma, Johns Hopkins University, Johnson & Johnson Innovation, John Wayne Cancer Institute, Joslin Diabetes Center, JS InnoPharm, Jubilant DraxImage, Juno Therapeutics, Junshi Biosciences, Jupiter Orphan Therapeutics, Juvenile Diabetes Research Foundation, JW Pharmaceutical, K-PAX Pharmaceuticals, Kadimastem, Kadmon Pharmaceuticals, KAHR Medical, Kaken Pharmaceutical, Kalbe Genexine Biologics, KaloBios Pharmaceuticals, Kalon Biotherapeutics, KalVista Pharmaceuticals, Kamada, Karuna Therapeutics, Karyopharm Therapeutics, Kazia Therapeutics, KBI BioPharma, Keck School of Medicine of USC, Kelun-Biotech Biopharmaceutical, KemPharm, Kennedy Trust For Rheumatology Research, Khandelwal Laboratories, Kiadis Pharma, Kineta, Kinex Pharmaceuticals, Kings College London, Kiniksa Pharmaceuticals, Kintor, Kissei Pharmaceutical, Kite Pharma, Kitov, Knight Therapeutics, Knopp Biosciences, Kodiak Sciences, Kolltan Pharmaceuticals, Kolon Life Science, Kowa Pharmaceuticals America, Kraig Biocraft Laboratories, Kuhnil Pharmaceuticals, Kura Oncology, KVK-Tech, Kwangdong Pharmaceutical, Kwang Dong Pharmaceutical, KYAN Therapeutics, Kymab, Kyongbo Pharm, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Kythera Biopharmaceuticals, Laboratories Acbel, LABORATORIOS SAVAL, Laekna, La Jolla Capital, La Jolla Pharmaceutical, Lannett, Lantheus Medical Imaging, Laurel Venture Capital, Laurent Pharmaceuticals, Lavasta Pharma, Leadiant Biosciences, Leaf Biopharmaceutical, Leap Therapeutics, Lee's Pharmaceutical, Lee Moffitt Cancer Center, Leiden University, Leona M and Harry B Helmsley Charitable Trust, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, Levo Therapeutics, Lexicon Pharmaceuticals, LFB Biomedicaments, LG Life Sciences, Libbs Farmaceutica, LIDDS, LifeCaring Technologies, LifeMax Laboratories, Life Science Korea, Ligand Pharmaceuticals, Lineage Cell Therapeutics, LineaRx, LingSheng Pharma Tech, Link Health, LIPAC Oncology, Lipid Therapeutics, Litha Pharma, LNE/G-Med, Locemia Solutions, Lonza, Los Altos Pharmaceuticals, Lotus Pharmaceuticals, Louisiana State University, Loxbridge Research, Loxo Oncology, LSK BioPharma, Ludwig Institute for Cancer Research, LumiThera, Lumosa Therapeutics, Lundbeck, Lund University, Lung Biotechnology, Lupin, Lupin Pharmaceuticals, Lupus Foundation of America (LFA), Lupus Research Alliance, Lupus Therapeutics, Luqa Pharmaceuticals, Lustgarten Foundation, Lycera, Lymphoma Study Association, MaaT Pharma, Mabion, MabVax Therapeutics, mAbXience, Macquarie University, MacroCure, Macrogenics, Magenta Therapeutics, Mallinckrodt Pharmaceuticals, MannKind Biopharmaceuticals, ManRos Therapeutics, Marrone Bio Innovations, Maruho, Massachusetts General Hospital, Massive Bio, Max-Delbruck Center for Molecular Medicine, MaxiVAX, Mayne Pharma, Mayo Clinic, McMaster University, McNeil Consumer Pharmaceuticals, MD Anderson Cancer Center, MDxHealth, Medac, Medeor Therapeutics, Medgenics, MEDIAN Technologies, Medical Developments International, Medical Marijuana, Medical Prognosis Institute, Medical University of Graz, Medical University of South Carolina, MedicaSafe, Medicenna Therapeutics, Medicines360, Medicines Patent Pool Foundation, MediciNova, Medicure, Medifocus, MediGene, Medimetriks, MedImmune, Medinova, Medison Pharma, Medisun International, Medivation, Medivir, MediWound, Medix, Medizone International, Medovex, Medpace, MedReleaf, Medtronic, Megapharm, Meiji Seika, MEI Pharma, Melanovus Oncology, Melinta Therapeutics, Melior Discovery, Memgen, Memorial Sloan Kettering Cancer Center, Menarini, Menlo Therapeutics, MenoGeniX, MentiNova, Merck and Co, Merck KGaA, Merck Serono, Merck Sharpe & Dohme, Mereo BioPharma, Merit Medical Systems, Meroven, Merrimack Pharmaceuticals, Mersana Therapeutics, Merz, Mesoblast, MetaboGen, Metuchen Pharmaceuticals, Meyer Children's Hospital of Florence, Mezzion Pharma, Michael J Fox Foundation, Microbiotix, MicuRx Pharmaceuticals, MikroLink, Millendo Therapeutics, Millennium, Milo Biotechnology, Mimetogen Pharmaceuticals, Mindstrong Health, Minerva Neurosciences, MinervaX, Minomic, Miraca Life Sciences, Miraculins, miRagen Therapeutics, Miragen Therapeutics, Mirati Therapeutics, Mirum Pharmaceuticals, Mission Bio, Mission Pharmacal, Mithra Pharmaceuticals, Mitsubishi Tanabe Pharma, Moberg Pharma, Moderna Therapeutics, Modern Biosciences, Moebius Medical, Moksha8, Molecular Templates, Moleculin Biotech, Molnlycke Health Care, Mologen, Molteni Farmaceutici, Monopar Therapeutics, Montreal Heart Institute, MorphoSys, Mor Research Applications, Motif Bio, Mount Sinai Health System, Mount Sinai Medical Center, MSD, MSD Biologics, Mucosis, Mundipharma, Munich Technical University, Mustang Bio, Mycovia Pharmaceuticals, Myeloma UK, Myeloproliferative Neoplasm Research Consortium, Mylan Laboratories, Mylan Pharmaceuticals, Mymetics, Myriad Genetics, Myrtle Potter & Company, myTomorrows, MyungMoon Bio, N1 Technologies, Nabriva Therapeutics, NacuGen Therapeutics, Nanning Xinzizhu Trading, Nanobiotix, NanoCarrier, Nanotherapeutics, NantCell, NantKwest, NASA, Natera, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Centre for Research and Development, National Eye Institute, National Heart, Lung and Blood Institute, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institutes of Health, National Organization for Rare Disorders, National Psoriasis Foundation, National Research Council Canada, National Space Biomedical Research Institute, National Surgical Adjuvant Breast and Bowel Project, National University Cancer Institute, Nationwide Children’s Hospital, Navidea Biopharmaceuticals, NCIC Clinical Trials Group, NCK, NCPC GeneTech, NEC, Nektar Therapeutics, Nemucore Medical Innovations, NeoImmuneTech, Neon Therapeutics, Neovacs, Nephrogenex, NerPharMa, Nerviano Medical Sciences, Nestle Health Science, NeuCyte, Neumedicines, Neumentum, Neuraltus Pharmaceuticals, NeurAxon, Neuraxpharm, Neuren Pharmaceuticals, Neuroblastoma and Medulloblastoma Translational Research, NeuroBo Pharmaceuticals, Neurocrine Biosciences, NeuroMetrix, NeuroPointDX, Neuropore Therapies, NeuroproteXeon, NeuroRx, NeuroSearch, NeuroSigma, Neurotrope BioScience, NeuroVive Pharmaceutical, NeuroVive Pharmaceutical Asia, Nevada Center For Behavioral Health, New Amsterdam Sciences, New England Research Institutes, Newlink Genetics, Newsoara Biopharma, New York Blood Center, New York Medical College, New York University, Neximmune, Nexvet, NGM Biopharmaceuticals, Nichi-Iko Pharmaceutical Co, Nico, Nicox, NIH Undiagnosed Diseases Program, Ningbo Tai Kang Medical Technology, Nippon Chemiphar, Nippon Kayaku, Nippon Shinyaku, Nitto Denko, NLS Pharmaceutics, Nogra Pharma, Nohla Therapeutics, Nordic Bioscience, Nordic Pharma Group, Norgine, Norsk medisinsk syklotronsenter, Northeast ALS Consortium, NorthSea Therapeutics, Nostrum Pharmaceuticals, Notable Labs, Novaliq, NovaMedica, Novan Therapeutics, Novartis, NovaSAID, Novasep, Novavax, Novella Clinical, NovellusDx, NovImmune, Novo, Novocure, Novo Nordisk, Novoteris, Noxxon Pharma, Nuevolution, Numedicus, NuSirt, Nutra Pharma, Nuvelution Pharma, Nuvilex, Nuvo Pharmaceuticals, NuvOx Pharma, Oakrum Pharma, Oberland Capital, OBI Pharma, Oblato, ObsEva, Ocugen, Oculis, Ocumension Therapeutics, Ocuphire Pharma, Ohio State University, Ohr Pharmaceuticals, Omega Pharma, OmniComm Systems, Omniox, Omnis Pharmaceuticals, Oncoceutics, OncoDNA, Oncoheroes Biosciences, Oncologie, Oncology Venture, Oncolytics Biotech, OncoMed Pharmaceuticals, OncoNano Medicine, Onconova Therapeutics, OncoQuest, OncoSec Medical, Oncosynergy, Oncotelic, Oncothyreon, Oncternal Therapeutics, Oncurious, Onegevity, One Way Liver Genomics (OWL), Ono Pharmaceutical, Ontario Clinical Oncology Group, Onxeo, Opiant Pharmaceuticals, OPKO Health, Opocrin S.p.A, OptiNose, Opus Bio, Oramed Pharmaceuticals, Orbit Biomedical, Orbsen Therapeutics, Orbus Therapeutics, Orchard Therapeutics, Oregon Health Sciences University, Orexigen Therapeutics, Orexo, Orgenesis, ORIC Pharmaceuticals, Orient EuroPharma, Origin Agritech, Origin Biosciences, Orion, OrphanDev, Ortho-Clinical Diagnostics, OSE Immunotherapeutics, OSE Pharma (Orphan Synergy Europe Pharma), Osivax, Ospedale San Raffaele, Otonomy, Otsuka, Ovid Therapeutics, Oxford BioMedica, OxyPharma, Paladin Labs, Palatin Technologies, Palobiofarma, Palvella Therapeutics, Panacea Biotech, Pan American Cancer Treatment Centers, Paragon Bioservices, Paratek Pharmaceuticals, Parent Project Muscular Dystrophy, Parexel, Parion Sciences, PARI Pharma, Parkinson's Institute and Clinical Center, Par Pharmaceutical, Patara Pharma, Patheon, Patheon N.V., Patient-Centered Outcomes Research Institute (PCORI),, Paul Scherrer Institute, PaxVax, PBM Capital Group, PCAS, PCG Clinical Services, PDC*line Pharma, PDS Biotechnology, PEAR Therapeutics, Pediatric Oncology Experimental Therapeutics Investigators Consortium, PegBio, PellePharm, Pendopharm, Penn Pharma, PepTcell, Peregrine Pharmaceuticals, PerkinElmer, Perlara, Pernix Therapeutics, Perrigo, Personal Genome Diagnostics, Personalis, Petra Pharma, Pfenex, Pfizer, PGI Drug Discovery, Phage Consultants, Pharco Pharma, PharmAbcine, PharmaCell, Pharmaceutics International, Pharmacosmos, Pharmacyclics, PharmaCyte Biotech, PharmaEssentia, Pharmalink AB, PharmaMar, Pharmanest, PharmaResearch Products, PharmaRoth Labs, Pharmathen, Pharmaxis, Pharmbio Korea, Pharming Group, Pharmstandard, Pharnext, PhaseBio Pharmaceuticals, Phathom Pharmaceuticals, Phenex, Pherin Pharmaceuticals, Phico Therapeutics, Phoenix Molecular Designs, Phosphate Therapeutics, Phosplatin Therapeutics, Phyton Biotech, Pieris, Pierre Fabre, Pierre Fabre Dermatologie, Pint Pharma, Piramal, Plandai Biotechnology, Plasticell, Plata Wellness, Plexxikon, Pluristem Therapeutics, POLA Pharma, Polpharma, Polyphor, Poniard Pharmaceuticals, Portal Instruments, Portola Pharmaceuticals, Poxel, PPD, Praxis, Prayog Labs, Precision Biologics, PredictImmune, Presage Biosciences, Prescient Medical, Presidio Pharmaceuticals, Prestige BioPharma, Prevacus, PreventionGenetics, PRIMA BioMed, Principia Biopharma, Privo Technologies, ProBioGen, Productos Científicos, Progenics Pharmaceuticals, Progenitor Cell Therapy, Progeria Research Foundation, Prokarium, Prometic Life Sciences, Promore Pharma, ProNAi Therapeutics, Pronova BioPharma, ProQR Therapeutics, Prosonix, Prostate Cancer Clinical Trials Consortium, Prostate Cancer Foundation (PCF), Protagonist Therapeutics, Protalix BioTherapeutics, Protext Mobility, ProtoKinetix, ProTrials Research, Provectus Biopharmaceuticals, Provention Bio, Proximagen Group, PSI (Population Services International), PsiOxus Therapeutics, Puma Biotechnology, Purdue Pharma, Pure MHC, Pyramid Biosciences, QED Therapeutics, Qiagen, Qilu Pharmaceutical, Quadrant Biosciences, QuantumLeap Healthcare Collaborative, Quantum Leap Health Care Collaborative, Quark Pharmaceuticals, Quimica Europea, Quintiles, R-Pharm, R-Tech Ueno, Radboud University Nijmegen Medical Centre, Radiation Therapy Oncology Group, Radius Health, Rafael Pharmaceuticals, Raiing Medical, Ranbaxy Laboratories, RAPT Therapeutics, RDD Pharma, Recipharm, Reckitt Benckiser, Recordati, Recro Pharma, RedHill Biopharma, Regenacy Pharmaceuticals, Regen BioPharma, Regenerative Medicine of Latin America, Regeneron Pharmaceuticals, Regenerx, Regeneus, Regenxbio, Regulus Therapeutics, Relief Therapeutics, Relmada Therapeutics, Relypsa, Remedy Pharmaceuticals, Renexxion, Replicel Life Sciences, Reproductive Medicine Associates of New York, ResearchDx, Research Institute of the Hospital Universitari Vall d'Hebron, ReShape Lifesciences, Resverlogix, Retrophin, Retrotope, Rett Syndrome Research Trust, Revolution Medicines, Revon Systems, Rexahn Pharmaceuticals, Rezolute, Rho, Rhythm Pharmaceuticals, Rigel Pharmaceuticals, Rising Pharmaceuticals, RMX Biopharma, Rochal Industries, Roche, Roche Consumer Health, Rocket Pharmaceuticals, Rockwell Medical, Roivant Sciences, Rosetta Genomics, RRD International, RSV, Rutgers University, RXi Pharmaceuticals, Sage Therapeutics, Sagimet Biosciences, Saint-Gobain Performance Plastics, Sajo Consulting, Salarius Pharmaceuticals, Salix Pharmaceuticals, Sam Chun Dang Pharm, Samsung Bioepis, Samsung Biologics, Samumed, Samyang Biopharmaceuticals, Sanaria, SanBio, Sandoz, Sanford Health, Sangamo BioSciences, Saniona, Sanofi, Sanofi-Pasteur, San Raffaele Telethon Institute for Gene Therapy, Santen Pharmaceutical, Santhera Pharmaceuticals, Sanuwave Health, Sarah Cannon Research Institute, Saraya, Sarepta Therapeutics, Satipharm, Sato Pharmaceutical, SATT Lutech, Savant HWP, Scancell, SciCann Therapeutics, SciClone Pharmaceuticals, Science 37, Scripps Research Institute, Scynexis, Seattle Genetics, Sedor Pharmaceuticals, Seelos Therapeutics, Seikagaku, Selecta Biosciences, Selexis, SELLAS Life Sciences Group, Selvita, Sema4, Senhwa Biosciences, Sensei Biotherapeutics, Seqirus, Sequential Medicine, Seren Pharmaceuticals, Seres Therapeutics, Sermonix Pharmaceutical, Serum Institute of India, Seven and Eight Biopharmaceuticals, Shandong Luoxin Pharma, Shanxi Yabao Pharmaceutical Distribution, Sheba Medical Center, Shenghuo Medical, Shenogen Pharma, Shenzhen BioScien Pharmaceuticals, Shenzhen Hepalink Pharmaceutical, Shenzhen Hybio Pharma, Shenzhen Royal Asset Management, Shenzhen Yuanxing Bio-Pharm Science & Technology, Shield Therapeutics, Shionogi, Shionogi Pharma, Shire Pharmaceuticals, Shuttle Pharmaceuticals, Sidero Bioscience, Sierra Oncology, SIFI (Societa Industria Farmaceutica Italiana), Sigma-Tau, Sigmoid, Signal Genetics, Silence Therapeutics, SillaJen, Simbec Research, Simcere Pharmaceuticals, Sinopharm, Sinopharm A-THINK Pharmaceutical, Sinovant Sciences, Sirnaomics, SiteOne Therapeutics, SK Biopharmaceuticals, Skyline Vet Pharma, Sloan Pharma, Small Business Innovation Research, SNBL CPC, Soin Neuroscience, Solasia Pharma, Soligenix, SOLTI, SomaGenics, SOM Biotech, Sonkei Pharmaceuticals, Sonnet BioTherapeutics, Sonoma Pharmaceuticals, Sophia Genetics, Soricimed Biopharma, Sorrento Therapeutics, Sosei, Sosei Heptares, Soterix Medical, South African Department of Health, Southern California Permanente Medical Group, Spark Therapeutics, Specialised Therapeutics, Specialized Medical Services-oncology, Spectrum Pharmaceuticals, Spero Therapeutics, Spirita Oncology, Spring Bank Pharmaceuticals, SpringWorks Therapeutics, SPR Therapeutics, St. Jude Children's Research Hospital, STADA Arzneimittel, Stallargenes, Stanford University, Stanford University School of Medicine, Starpharma, Staten Biotechnology, SteadyMed Therapeutics, Stealth Therapeutics, Stellar Biotechnologies, St George Street Capital, Strata Oncology, Strategic Science and Technologies, Strides Arcolab, Strongbridge Biopharma, Sucampo AG, Sucampo Pharmaceuticals, Summit Therapeutics, SunGen, Sunovion Pharmaceuticals, Sun Pharmaceutical, Sunshine Biopharma, Sunstone Capital, SunTerra Biotechnology, Surefire Medical, SurModics, Sutro Biopharma, Swedish Bactiguard, Swedish Orphan Biovitrum, Sydys Corporation, SymBio Pharmaceuticals, Synairgen, Synapcell, Synartro, SynCo Bio Partners, Syndax Pharmaceuticals, Synergy Pharmaceuticals, Synlogic, Syntano Technology Venture, Synteract, Synthetic Biologics, Syntrix Biosystems, Syros Pharmaceuticals, T3D Therapeutics, Taiba, TaiGen Biotechnology, Taiho, Taisho Pharmaceutical, TaiwanJ Pharmaceuticals, Takeda Pharmaceutical, Tanner Pharmaceuticals, TapImmune, Tara Immuno-Oncology, Targacept, Target ALS Foundation, Targeted Therapy Technologies, TARGET PharmaSolutions, TARIS Biomedical, Tarrex Biopharma, Tasly Pharmaceuticals, Tavotek Biotherapeutics, Taxus Cardium Pharmaceuticals, Taxus Pharmaceuticals, Team Sanfilippo, Technology Strategy Board (UK), TEDOR Pharma, Teijin, Teikoku Pharma USA, Tekmira Pharmaceuticals, Tel Aviv Sourasky Medical Center, Telesta Therapeutics, Telix Pharmaceuticals, Tempus, Terns Pharmaceuticals, Terumo, Tesaro, TesoRx Pharma, Tessa Therapeutics, Tetra Bio-Pharma, Tetra Discovery Partners, TetraLogic Pharmaceuticals, Tetraphase Pharmaceuticals, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, TFS International, TG Therapeutics, The Medicines Company, Themis Bioscience, The Nemours/Alfred I duPont Hospital for Children, The Parker Institute For Cancer Immunotherapy, Theradiag, Theralase, Theramex, TherapeuticsMD, Therapix Bio, Theravance, TheraVida, The Regents of the University of California, Thermo Fisher Scientific, Thomas Jefferson University, Thorne Research, Threshold Pharmaceuticals, ThromboGenics, Tianhe Stem Cell Biotechnologies, Tianjin CanSino Biotechnology, Tiburio Therapeutics, TiGenix, Tilray, TILT Biotherapeutics, Titan Pharmaceuticals, Tiziana Life Sciences, TMRC, Tocagen, Tolero Pharmaceuticals, Tonghua Dongbao Pharma, TONIX Pharmaceuticals, Topstone Research, Torii Pharmaceutical, Torque Therapeutics, Torrent Pharmaceuticals, TRACON Pharmaceuticals, Transcenta, Transgene, Transition Therapeutics, Translational Sciences, Transplant Genomics, Trek Therapeutics, Treos Bio, Trethera, Trevena, Trevi Therapeutics, TRIGR Therapeutics, Trillium Therapeutics, Triphase Accelerator, Tris Pharma, Triumvira Immunologics, Trizell, TrovaGene, True Diagnostics, Trulieve, TTY Biopharm, Turnstone Biologics, TxCell, Tyme Technologies, UCB, UCL Business, Uluru, UMass Memorial Medical Center, Uni-Bio Science, Unified Women's Clinical Research, UniQure, United Therapeutics, University College London, University Health Network, University Hospital Carl Gustav Carus Dresden, University Medical Center Groningen, University of Alabama at Birmingham, University of Auckland, University of Barcelona, University of Bergen, University of Birmingham, University of British Columbia, University of California, University of California, San Diego, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Colorado, University of Edinburgh, University of Illinois, University of Illinois at Chicago, University of Liverpool, University of Maryland, University of Maryland Baltimore, University of Massachusetts, University of Massachusetts Medical School, University of Melbourne, University of Michigan, University of Minnesota, University of New South Wales, University of North Texas Health Science Center, University of Oxford, University of Pennsylvania, University of Rochester Medical Center, University of Southern California, University of Texas Southwestern Medical Center, University of Utah, University of Washington, University of Western Sydney, University of Wisconsin, University of Wisconsin Carbone Cancer Center (UWCCC), Unum Therapeutics, Upsher-Smith, Urology San Antonio, Urovant Sciences, US Army Medical Research Institute of Chemical Defense, US Army Medical Research Institute of Infectious Diseases, US Department of Veteran Affairs, US Oncology, US Oncology Research, UTILITY Therapeutics, Vaccine and Gene Therapy Institute of Florida (VGTI-FL), Vaccinex, Vaccitech, Valeant Pharmaceuticals, Valneva, Varifarma, Vasamed, Vaxart, Vaximm, VBI Vaccines, VBL Therapeutics (dba), Vcell Healthcare, V ClinBio, Vector Oncology, Vectura, Vedanta Biosciences, Velo Bio, Veloxis Pharmaceuticals, VenatoRx, Verastem, Vericel, Verisante Technology, Vernalis, Versartis, Vertex Pharmaceuticals, ViaCyte, VIB, Vical, Videregen, Viela Bio, Vifor-Fresenius Medical Care Renal Pharma Ltd, Vifor Pharma, ViiV Healthcare, Viralytics, ViraTherapeutics, Virbac, Vir Biotechnology, Virginia Tech Carilion Research Institute, Viriom, ViroXis, VirtualScopics, VistaGen Therapeutics, Visterra, Vitaeris, Vitrisa Therapeutics, ViveBio, Vivelix Pharmaceuticals, Viz.ai, VM Pharma, VolitionRX, Voyager Therapeutics, vTv Therapeutics, Vyera Pharmaceuticals, Vyriad, Walter Reed Army Institute of Research, Wanbang Biopharmaceuticals, Washington State University, Washington University in St Louis, WCCT Global, Weihai Weigao Medical Devices, Wellcome Trust, Westmead Institute for Medical Research, WideTrial, Wilex, WindMIL Therapeutics, Windtree Therapeutics, Winhealth Pharma Group, WIRB-Copernicus Group, Wize Pharma, Women & Infants Hospital of Rhode Island, Woolsey Pharmaceuticals, Worldwide Clinical Trials, WPD Pharmaceuticals, Wuxi Apptec Laboratory Services, WuXi Biologics, X4 Pharmaceuticals, XBiotech, Xbrane Bioscience, Xcede Technologies, Xenon Pharmaceuticals, Xenoport, XERIS Pharmaceuticals, Xianju Pharmaceutical, Xinogen, Xisle Pharma Ventures Trust, Xoma, Xortx Pharma, Xspray Pharma, Xynomic Pharmaceuticals, Y-mAbs Therapeutics, Yabao Pharmaceutical, Yakult Honsha, Yale University, Yas Holding, Yiling Wanzhou International Pharmaceuticals, Yisheng Biopharma, Yissum Research Development, YL Biologics, YOFOTO (China) Health Industry, Yoshindo, Yuhan Corporation, Yungjin Pharmaceutical, ZAI Laboratory, ZAO Firma Euroservice, Zenith Epigenetics, Zenith Technologies, Zenoaq, Zenon Biosystem, Zenosense, Zenyaku Kogyo, Zeria Pharmaceuticals, ZetrOZ, Zhejiang Hisun Pharmaceutical, Zhittya Genesis Medicine, Ziarco Pharma, Zimmer Biomet, Zogenix, Zosano Pharma, Zydus Cadila, Zymeworks
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Collaborative R&D
• Contract service
• Equity purchase
• Joint venture
• Royalty financing
• Spin out
• Sub license
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.